Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory Phase IIa Study of Oral FX125L in Chronic Inflammatory Disease
2011-005036-26Phase 2Terminated
- Sponsor
- Funxional Therapeutics
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma, rheumatoid arthritis (RA) and chronic inflammatory conditions comparing FX125L 600 mg once daily with Placebo (2 arms). Primary endpoints: Biological response to FX125L vs placebo and Safety of FX125L 600 mg once daily. Started Oct 2011; status: terminated.
02
Drugs
FX125L
03
Conditions
asthmarheumatoid arthritis (RA)chronic inflammatory conditions
Beyond the preview
Go deeper on 2011-005036-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005036-26.